Palisade bio is granted fast track designation from the u.s. food and drug administration for lb1148 for accelerated return of bowel function following gi surgery

Carlsbad, ca, nov. 22, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for avoidance of acute and chronic post-surgical complications following gastrointestinal (gi) surgery, today announced that the u.s. food and drug administration (fda) has granted fast track designation to lb1148 for the acceleration of time to return of bowel function following surgery.
PALI Ratings Summary
PALI Quant Ranking